George McClung

Staff Scientist

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2025

Mass Spectrometry Imaging (MSI) is an emergent tool for analyzing spatial molecular distributions, yet data complexity often hinders effective analysis. MSI.EAGLE, an open-source R-Shiny application, makes analysis accessible for non-specialists by integrating advanced tools in a user-friendly interface. The workflow leverages tools from the Cardinal MSI package, with enhanced phenotyping, segmentation, statistical analysis and visualization. The application addresses a gap in spatial biology research by empowering a broader scientific community.

Year:

2025

Glypican-3 (GPC3) is a proteoglycan with high sensitivity and specificity for hepatocellular carcinoma (HCC). We describe the integrated development and validation of a GPC3-targeting optical imaging probe and T cell–redirecting antibody (TRAB) as a theranostic strategy for the detection and treatment of HCC. A novel TRAB targeting GPC3 on HCC tumor cells and the CD3 T-cell receptor as well as a distinct GPC3-specific optical imaging probe were developed from a short peptide. The efficacy of GPC3/CD3 TRAB was evaluated in vitro using IFNγ release and calcein-AM assays. Patient-derived xenografts were used to assess the in vivo efficacy of GPC3/CD3 TRAB and the GPC3 imaging probe for the detection of GPC3+ HCC. GPC3/CD3 TRAB caused a dose-dependent escalation in IFNγ release from inactive peripheral blood T cells (P = 0.001) and higher tumor-cell lysis (P = 0.01) compared with controls in vitro. Intratumorally injected GPC3/CD3 TRAB resulted in significant prolongation of tumor doubling time in the GPC3+ tumors, with an associated reduction of tumor fluorescent signal from the HiLyte 488–conjugated GPC3-specific peptide on optical imaging. These data demonstrate that HCC cell targeting using a GPC3/CD3 TRAB derived from a small peptide enabled effective T-cell activation and induction of a cytotoxic response toward GPC3+ HCC tumor cells both in vitro and in vivo. GPC3-specific optical imaging enabled the detection of the GPC3+ HCC cells and noninvasive monitoring of tumor response to adoptive immunotherapy. The integrated development of a targeted therapeutic and molecular imaging probe provides a promising paradigm for the development of cancer theranostics.

Year:

2024

Deficit of oxygen and nutrients in the tumor microenvironment (TME) triggers abnormal angiogenesis that produces dysfunctional and leaky blood vessels, which fail to adequately perfuse tumor tissues. Resulting hypoxia, exacerbation of metabolic disturbances, and generation of an immunosuppressive TME undermine the efficacy of anticancer therapies. Use of carefully scheduled angiogenesis inhibitors has been suggested to overcome these problems and normalize the TME. Here, we propose an alternative agonist-based normalization approach using a derivative of the C-type natriuretic peptide (dCNP). Multiple gene expression signatures in tumor tissues were affected in mice treated with dCNP. In several mouse orthotopic and subcutaneous solid tumor models including colon and pancreatic adenocarcinomas, this well-tolerated agent stimulated formation of highly functional tumor blood vessels to reduce hypoxia. Administration of dCNP also inhibited stromagenesis and remodeling of the extracellular matrix and decreased tumor interstitial fluid pressure. In addition, treatment with dCNP reinvigorated the antitumor immune responses. Administration of dCNP decelerated growth of primary mouse tumors and suppressed their metastases. Moreover, inclusion of dCNP into the chemo-, radio-, or immune-therapeutic regimens increased their efficacy against solid tumors in immunocompetent mice. These results demonstrate the proof of principle for using vasculature normalizing agonists to improve therapies against solid tumors and characterize dCNP as the first in class among such agents.

Year:

2024

Supplementary Figure 4: In-Vivo treatment schedule of injections and imaging. After i.p. injection of saline or T-cells, tumors were injected with saline, scGPC3/CD3, or the GPC3/CD3 bispecific antibody every 12 hours for a total of five injections. This serial injection sequence was repeated on the fourth day following the first injection. Mice were euthanized on day 14 with tumor tissues preserved for histology.

Year:

2024

Supplementary Figure S1: Expression and Purification of TRAB Recombinant Protein. Synthesized TRAB gene fragments (IDT DNA, Coralville, IA), as specified in figure above (A), were inserted into a pTXB1 (New England Biolabs) vector using standard restriction enzyme based cloning techniques. Insertion of the TRAB sequence was verified by DNA sequencing using the T7 promoter as the sequencing primer. The TRAB-pTXB1 plasmids were then transformed into a competent E coli expression cell line (Origami 2 Cells, Novagen). Bacterial cell cultures were initially grown overnight in an air shaker (225 rpm) at 37°C in 3 mL of lysogeny broth (LB) media, eventually inoculated into scaled up 1 L LB media containing 50 mg/L of ampicillin. At optical density (OD) 600 nm = 0.6, Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures were allowed to express for 2 h at 37°C. Bacterial cultures were centrifugally pelleted at 10,000 g for 30 min, resuspended in 5 mL of column buffer (20 mM Na-HEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cell lysate was centrifuged at 15,000 g for 30 min at 4°C. Supernatant was then loaded and incubated in Poly-Prep chromatography column (Bio-Rad, Hercules, CA) packed with Talon metal affinity resin (Clontech, Mountain View, CA). Supernatant was then allowed to pass through the column and resin beads were washed with multiple rounds of column buffer (0.1 M Tris-HCl, pH 8.5). Bound and washed TRAB protein (sequence shown in panel B) was then released from metal resin via the addition of 200 mM imidazole-containing elution buffer. Purification and concentration of the final product was performed using a 3 kDa molecular weight cutoff (MWCO) filter (Amicon Ultra, Milipore, Temecula, CA). The final product was analyzed on SDS-PAGE protein gel (Figure 2), with confirmation of the protein band at the expected molecular weight.

Year:

2024

Supplementary Figure S3: GPC3-specific targeting peptide has a similar binding pattern to HCC samples compared to immunostaining with GPC3 antibody. (A-D) Representative contiguous slides from HCC samples stained with GPC3 antibody (A, B) and GPC3-specific peptide (C, D) demonstrate similar staining patterns. HCC, hepatocellular carcinoma.

Year:

2024

Supplementary Figure S2: GPC3 expression in HCC samples and normal adjacent liver. Sample images from immunostaining showing nearly absent GPC3 expression in normal adjacent liver (n=41) (A, B) and high GPC3 expression in HCC tumors (n=47) (C,D). 79% of the tumors (79%) stained strongly positive for GPC3 expression (Grade 3 and 4) (E). Within normal adjacent liver samples only 2 (5%) had grade 3/4 GPC3 expression compared to 79% among HCC tumor samples (F).

Year:

2024

Glypican-3 (GPC3) is a proteoglycan with high sensitivity and specificity for hepatocellular carcinoma (HCC). We describe the integrated development and validation of a GPC3-targeting optical imaging probe and T cell–redirecting antibody (TRAB) as a theranostic strategy for the detection and treatment of HCC. A novel TRAB targeting GPC3 on HCC tumor cells and the CD3 T-cell receptor as well as a distinct GPC3-specific optical imaging probe were developed from a short peptide. The efficacy of GPC3/CD3 TRAB was evaluated in vitro using IFNγ release and calcein-AM assays. Patient-derived xenografts were used to assess the in vivo efficacy of GPC3/CD3 TRAB and the GPC3 imaging probe for the detection of GPC3+ HCC. GPC3/CD3 TRAB caused a dose-dependent escalation in IFNγ release from inactive peripheral blood T cells ( P = 0.001) and higher tumor-cell lysis ( P = 0.01) compared with controls in vitro . Intratumorally injected GPC3/CD3 TRAB resulted in significant prolongation of tumor doubling time in the GPC3+ tumors, with an associated reduction of tumor fluorescent signal from the HiLyte 488–conjugated GPC3-specific peptide on optical imaging. These data demonstrate that HCC cell targeting using a GPC3/CD3 TRAB derived from a small peptide enabled effective T-cell activation and induction of a cytotoxic response toward GPC3+ HCC tumor cells both in vitro and in vivo. GPC3-specific optical imaging enabled the detection of the GPC3+ HCC cells and noninvasive monitoring of tumor response to adoptive immunotherapy. The integrated development of a targeted therapeutic and molecular imaging probe provides a promising paradigm for the development of cancer theranostics.

Year:

2024

Collaborators (8)

Garret A. FitzGerald

University of Pennsylvania

UNITED STATES
View details

David Cormode

Professor

University of Pennsylvania

UNITED STATES
View details

Kelley Weinfurtner

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Terence Gade

PI

University of Pennsylvania

UNITED STATES
View details

Daniel Ackerman

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Andrew Tsourkas

Professor

University of Pennsylvania

UNITED STATES
View details

Ioannis Verginadis

Scientist

University of Pennsylvania

UNITED STATES
View details

David Kaplan

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details